15 results about "Cellular formation" patented technology

The present disclosure relates to a method of generating pancreatic lineage cells, e.g. islet-like cell aggregates comprising pancreatic beta cells, comprising the steps of providing a single cell suspension of a population of endocrine progenitor cells (EP), allowing the EP cells in the single cell suspension to form 3D structures, and culturing the cells under conditions allowing differentiation into pancreatic mono-hormonal beta cells. The present disclosure also relates to islet-like cell aggregates obtainable by said method and their medical use.

The invention relates to an establishment method of a high-fat induced intestinal organ injury model and an injury intervention method for the model. The establishment method comprises the following steps: step A, preparation: preparing colon cells, PBMC cells and an organ-like culture chip for later use; step B, colon barrier construction: inoculating colon cells to the surface of a barrier membrane on the lower side of a culture chip by using an organoid culture chip to obtain a colon barrier model; step C, constructing a co-culture model, and inoculating PBMC cells to the basal side of the colon barrier on the basis of the colon barrier to obtain a human colon barrier-PBMC co-culture model; d, constructing a damage model, and performing damage treatment on the co-culture model by using a treating fluid to obtain the damage model; according to the invention, the barrier function organ-like chip is used, a human intestinal cell-PBMC co-culture model is formed by utilizing human intestinal organs and PBMC cells, and OXLDL / palmitic acid can play a role in an injured intestinal organ barrier model and form a high-fat induced intestinal organ injury model through the prepared injury treating fluid.

The invention discloses a bionic gastric mucosa micro-barrier structure, comprising: a bottom microfluidic channel for simulating a submucosal vascular network; the middle gastric epithelial cell layer is used for simulating a mucous membrane epithelial barrier and comprises a matrix layer, quaternary functional cells, a culture medium and a pH buffer module; and the surface dynamic mucus layer is used for simulating a mucous membrane protective barrier and comprises a vagus neurotransmitter simulant, exogenous mucus and a pressure sensor. According to the invention, continuous nutrition supply is provided for the middle gastric epithelial cell layer through the bottom microfluidic channel, the survival and functions of cells are maintained, and accurate tracking of the transgastric mucosa transport process is realized. A function collaborative network is formed through quaternary cells, the secretion volume and the injury state are monitored in real time, regulatory factors are dynamically adjusted, and it is ensured that a cell layer can still maintain the barrier function stable under external interference. When foreign matter impact or food friction signals are recognized through the pressure sensor, the pump speed is instantly increased, and local mucus loss is rapidly supplemented.

The application discloses application of FTY720 as a PP2A phosphatase activator in preparation of a medicine for treating type I neurofibromatosis. The application first uses FTY720 for treatment of type I neurofibromatosis, and proves that FTY720 significantly inhibits formation of neurofibromas by non-specifically activating PP2A phosphatase. In-vivo experimental results show that FTY720 as a single drug can significantly inhibit tumor growth, and a synergistic effect is presented when FTY720 is combined with a MEK inhibitor, and tumor growth is almost completely inhibited. In-vitro cell experiments show that FTY720 as a single drug or in combination with MEKi treatment can inhibit tumor Schwann cells from forming tumor spheres, inhibit cell proliferation and migration, and induce tumor cell apoptosis. The application overcomes the drug resistance problem existing in the prior art MEK inhibitor, and provides a new treatment strategy for type I neurofibromatosis. FTY720 is an FDA-approved drug, and has good safety and drugability, and has high clinical conversion potential.

[Object] Provided is a culture solution for promoting immune improvement and normal immune formation that promote healthy immune formation of humans and cure allergic diseases such as atopic dermatitis, and a culture solution generator capable of easily generating the culture solution. [Solving Means] A culture solution generator 1 generating a culture solution for promoting immune improvement and normal immune formation, the culture solution obtained by suspending 300 g or more of Bacillus fermented powder in 150 liters of water, maintaining a temperature of 30 to 45°C, and supplying oxygen with an oxygen saturation of 70% or more for fermentation.

The present disclosure relates to a method for the generation of cells of the pancreatic lineage, for example pancreatic islet-like cell aggregates comprising pancreatic β-cells, which method comprises the steps of providing a single cell suspension of a population of endocrine progenitor (EP) cells, allowing said EP cells in single cell suspension to form 3D structures and culturing said cells under conditions permissive of differentiation into pancreatic monohormonal β-cells. The present disclosure also relates to pancreatic islet-like cell aggregates obtainable by said method as well as to medical uses thereof.

The invention belongs to the technical field of primary cell culture, and particularly relates to a bronchial epithelial cell physiological or pathological model and a construction method and application thereof.The construction method comprises the steps that primary HBECs are provided, an amplification culture medium is used for conducting infiltration type amplification culture on the HBECs in a cell culture plug-in, after the cells form a complete barrier, the amplification culture medium is removed, and the model is obtained; carrying out gas-liquid interface culture on the cells in the cell culture plug-in by adopting a differential culture medium so as to induce the differentiation of the HBECs to form a false multi-layer columnar epithelial tissue structure; the cell culture plug-in comprises a porous membrane substrate, and construction of a physiological model or a pathological model is realized by selecting the cell culture plug-in of the porous membrane substrate with different pore diameters. According to the method, the in-vitro differentiation period of the HBECs can be remarkably shortened, and the model culture efficiency is greatly improved. The bronchial epithelium model capable of accelerating physiological differentiation or having pathological phenotype prepared by the method provided by the invention has significant advantages in drug screening and disease research.

The invention relates to the field of biological medicines, in particular to a TCR55 mutant and application thereof.The TCR55 mutant comprises an alpha chain and a beta chain, the TCR55 mutant is obtained after mutation is conducted on the basis of wild TCR55, and the alpha chain of the TCR55 mutant is a mutant obtained after any one of the following sites on the alpha chain of the wild TCR55 is mutated into histidine, the fourth position D and / or the fifth position E of the CDR2 alpha, and the seventh position A of the CDR3 alpha; or the beta chain of the TCR55 mutant is a mutant obtained by mutating any one of the following on the beta chain of the wild type TCR55 into histidine: the second site N of CDR1beta, the second site A of CDR2beta, the fourth site E and / or the sixth site T of CDR2beta, and the thirteenth site Y of CDR3beta. The mutant can be used for identifying HIV (Pol448-456) / HLA-B35, has high activating power, triggers downstream signal transduction, and can be used for transforming T cells to form specific high-activating-power TCR-T cells for T cell adoptive immunotherapy.

The application relates to the fields of biotechnology and targeted therapy, and particularly relates to a recombinant construct, a CAR-T cell and construction and application thereof. The application verifies the role and mechanism of THEMIS in maintaining the long-term killing of tumor cells of CAR-T through experiments. The CAR-T cell overexpressing THEMIS is constructed, compared with a control group, the proliferation capacity and memory cell formation capacity of the THEMIS-7x19 CAR-T cell are enhanced after antigen stimulation, and the cytokines are in a controllable state, the cell apoptosis and exhaustion are reduced, and the long-term tumor killing capacity can be maintained more effectively. The in-vivo experiment also proves that the THEMIS-7x19 CAR-T cell has stronger anti-tumor effect compared with the control group in a lymphoma tumor-bearing mouse model, and the survival time of the mouse is significantly prolonged.

The application discloses a HeLa cell three-dimensional culture model, a preparation method and application. HeLa cells are mixed with a collagen-sodium alginate composite hydrogel precursor solution to obtain a cell-precursor mixture, the cell-precursor mixture is mixed with a CaCl2 solution to obtain a mixed solution, and the mixed solution is placed in an incubator for standing culture for 10-60 min, so that the hydrogel is cross-linked and solidified to form a three-dimensional culture system; complete culture medium is further added for continuous culture, and a HeLa cell three-dimensional culture model is constructed. The HeLa cell three-dimensional culture model is constructed by using the hydrogel, defects existing in simulation of a tumor microenvironment by two-dimensional culture and an animal model are effectively solved, the body microenvironment can be better simulated, cells form regular three-dimensional cell spheroids, a malignant phenotype is maintained, the accuracy and repeatability of drug screening are improved, and a reliable technical platform is provided for cervical cancer mechanism research and anti-tumor drug screening.

The invention relates to cell biology and regenerative medicine, specifically to a culture method and application for porcine limbal epithelial stem cells. The method involves pretreatment of cells, coating of culture dishes, centrifugation, culturing, passaging, and identification by immunofluorescence staining. The cultured cells are applicable in repairing corneal diseases, including limbal stem cell deficiency. During repair, the cells can be combined with biological materials to form a stem cell engineering carrier for implantation at the injury site. The separation and culture method is simple, yields a large number of cells, and is suitable for use with porcine eyeballs. Limbal epithelial stem cells cultured in vitro form distinct cell clusters, referred to as stem cell islands. The obtained cells exhibit phenotypes including BMI1+, ΔNp63α+, CK14+, and ABCG2+. Based on experimental and clinical research, this method provides a promising approach for cell transplantation in ocular surface reconstruction.

The invention relates to a ZIF-8 nano-enzyme with a Ce-luteolin coordination coating as well as a preparation method and application of the ZIF-8 nano-enzyme, and belongs to the technical field of biological medicines and nano-materials. The nano enzyme is constructed by adopting a step-by-step loading-coordination assembly strategy: firstly, synthesizing ZIF-8 nano particles as an inner core; then luteolin is introduced and adsorbed to pores and the surface of ZIF-8; finally, cerium ions are introduced, and the dense Ce-luteolin metal-organic coordination coating is formed on the surface of the ZIF-8 through in-situ growth by means of the strong coordination effect of phenolic hydroxyl groups and carbonyl groups in luteolin molecules and the cerium ions. The nano-enzyme has excellent SOD-like and CAT-like activities, and effectively inhibits foam cell formation, regulates endothelial cell senescence-related secretory phenotype (SASP) and alleviates DNA damage through an ROS removal-anti-inflammatory-anti-aging synergistic mechanism. The invention provides a new multi-target nano intervention strategy for the treatment of atherosclerosis.

The invention relates to a dibenzocyclooctyne modified tumor antigen, an anti-tumor vaccine and application of the dibenzocyclooctyne modified tumor antigen and the anti-tumor vaccine. The DBCO modified tumor antigen has an adjuvant effect, and the DBCO modified tumor antigen or the protein vaccine can promote DC antigen presentation and T cell activation, improve CTL killing activity and promote memory T cell formation by activating an NF-kB / iNOS signal axis, so that the tumor immunoprophylaxis and treatment effects of the tumor vaccine can be remarkably improved. Meanwhile, the DBCO modified tumor antigen or the tumor vaccine can remodel the tumor microenvironment through lung tissue targeting, significantly inhibit the progress of pulmonary metastatic tumors, and can synergistically enhance the curative effect of treating tumors by being combined with an immune checkpoint inhibitor. The invention provides a novel immune regulation strategy for the development of chemically modified vaccines, and has important significance in the field of anti-tumor treatment.

The application belongs to the technical field of biomedical material engineering, and discloses a hydrogel support for 3D tumor sphere culture and drug screening, which is formed by four-arm polyethylene glycol maleimide, fibrinogen and thrombin through Michael addition cross-linking and biological polymerization cooperation, and has an adjustable elastic modulus of 10-1000 Pa by adjusting the proportion of each component, and the gelation is completed within 5 minutes at room temperature. The support has the biological activity of fibrin and the structural stability of polyethylene glycol, can efficiently support HCT116 cells to form high-vigor tumor spheres, accurately simulates the in-vivo tumor microenvironment, significantly improves the accuracy and repeatability of drug screening, is simple to operate and compatible with the high-throughput platform of standard well plates, and is suitable for the drug sensitivity detection of tumor personalized treatment.

The invention discloses a bispecific antibody DLK1 / CD3 for treating liver cancer. The bispecific antibody DLK1 / CD3 comprises an anti-human DLK1 monoclonal antibody and an anti-human CD3 monoclonal antibody. The sequence of the single-chain variable region of the DLK1 monoclonal antibody and the single-chain variable region of the CD3 monoclonal antibody is VL (DLK1)-VH (DLK1)-VH (CD3)-VL (CD3). The bispecific antibody can form immune synapses by targeting tumor cells and T cells, directly activate the T cells and enhance the killing ability of the T cells to liver cancer cells.